SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Rachel Carson

PatientRachel Carson
Date of birth1973-05-27
IdentifiersMRN HR-ML041-SYN; SSN (made up) 000-41-5068
Document date2026-06-15
AuthorMargaret Vance-Okonkwo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Start of letrozole, ribociclib, and zoledronic acid after radiation. [S]

History of Present Illness

Ms. Carson completed whole-breast and regional nodal radiation with a tumor-bed boost two and a half weeks ago, in 19 afternoon sessions, with mild reddening of the skin that has faded. She kept writing in the mornings throughout. Her dental check last week was normal. Today she starts letrozole and the first 28-day cycle of ribociclib, and has her first zoledronic acid infusion. She has read the side-effect sheets and asked for the monitoring schedule in writing, which she was given. She has mild morning knee stiffness, unchanged, and no hot flashes. She takes no other medicines and no grapefruit or herbal products. [S]

ElementDetail
Interval changeRadiation completed two and a half weeks ago
SkinGrade 1 reddening, now faded
TodayLetrozole and ribociclib cycle 1 day 1; first zoledronic acid infusion
DentalDental check last week normal
InteractionsNo QT-prolonging drugs, strong CYP3A inhibitors, grapefruit, or herbal products

Review of Systems

SystemResultFinding
ConstitutionalPositiveMild tiredness after radiation, improving
IntegumentaryNegativeRadiation reddening faded; no blistering
CardiovascularNegativeNo palpitations, fainting, or chest pain
MusculoskeletalPositiveMild morning knee stiffness, baseline before letrozole; no bone pain
GenitourinaryNegativeNo vaginal dryness or bleeding
PsychiatricNegativeMood steady

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healingOne capsule once daily before breakfastOral route2026-01-19 to 2026-04-03completedS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2025-06-02activeS
Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five yearsOne tablet once dailyOral route2026-06-15activeS
Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three yearsTwo tablets once daily on days 1 to 21 of each 28-day cycleOral route2026-06-15activeS
Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three yearsOne infusion every six monthsIntravenous route2026-06-15activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-06-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-15Body height163cmS
2026-06-15Body weight58.9kgS
2026-06-15Body mass index (BMI) [Ratio]22.2kg/m2S
2026-06-15Systolic blood pressure120mm[Hg]S
2026-06-15Diastolic blood pressure76mm[Hg]S
2026-06-15Heart rate70/minS
2026-06-15Respiratory rate14/minS
2026-06-15Body temperature36.6CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-15Hemoglobin [Mass/volume] in Blood12.8g/dL12-15.5 g/dLNormalS
2026-06-15Leukocytes [#/volume] in Blood by Automated count5.910*3/uL4-11 10*3/uLNormalS
2026-06-15Neutrophils [#/volume] in Blood by Automated count3.410*3/uL1.8-7.7 10*3/uLNormalS
2026-06-15Platelets [#/volume] in Blood by Automated count24010*3/uL150-400 10*3/uLNormalS
2026-06-15Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-06-15Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L<=33 U/LNormalS
2026-06-15Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L<=32 U/LNormalS
2026-06-15Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL<=1.2 mg/dLNormalS
2026-06-15Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-06-15Magnesium [Mass/volume] in Serum or Plasma2.1mg/dL1.7-2.4 mg/dLNormalS
2026-06-15Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-06-15Cholesterol [Mass/volume] in Serum or Plasma208mg/dL<=199 mg/dLHighS
2026-06-15Cholesterol in HDL [Mass/volume] in Serum or Plasma62mg/dL>=50 mg/dLNormalS
2026-06-15Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation124mg/dL<=99 mg/dLHighS
2026-06-15Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2026-06-1525-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma22ng/mL30-100 ng/mLLowS
2026-06-15Q-T interval corrected418msRibociclib is started only when QTcF is below 450 msNormalS
2026-06-15DXA Lumbar spine [T-score] Bone density-1.8{T-score}>=-1LowS
2026-06-15DXA Femur [T-score] Bone density-1.3{T-score}>=-1LowS

Physical Exam

Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell
BreastsLeft breast with faint tanning and mild firmness after radiation; scar healed; no masses. Right breast normal
Lymph nodesNo axillary or supraclavicular nodes
ExtremitiesArm circumference 25.5 cm on each side; full shoulder movement; knees with mild crepitus, no effusion
MouthTeeth and gums in good repair

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1960 breast cancer, which was not disclosed to heractiveconfirmed C50.412S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy bookedresolvedconfirmed N63.21S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D).
Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure plannedresolvedconfirmed K26.9S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date.
Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shoreactiveconfirmed M17.0S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private.
Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17activeconfirmed C77.3S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used.
Long-term use of letrozole as adjuvant endocrine therapy, with ribociclib for three yearsactiveconfirmed Z79.811S — Synthetic treatment status.
Low bone mass (osteopenia) on baseline DXA before letrozole: lumbar spine T-score -1.8, femoral neck -1.3; 10-year major osteoporotic fracture risk about 7 percent (FRAX); vitamin D insufficiencyactiveconfirmed M85.80S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyECG before ribociclibBefore the first dose; start only if QTcF is below 450 msCompleted todayQTcF 418 ms, sinus rhythm 70/min
LaboratoryBlood count before ribociclibBefore the first dose, then every 2 weeks for 2 cyclesCompleted todayWhite cells 5.9, neutrophils 3.4, hemoglobin 12.8, platelets 240
LaboratoryLiver tests before ribociclibBefore the first dose, then every 2 weeks for 2 cyclesCompleted todayALT 20, AST 22, bilirubin 0.6
LaboratoryElectrolytes before ribociclibBefore the first dose and at the start of each of the first 6 cyclesCompleted todayPotassium 4.2, magnesium 2.1, calcium 9.4
Medication safetyInteraction review: QT-prolonging drugs and strong CYP3A inhibitorsAt the start and with every new medicineCompleted todayNone taken; written list given
Medication safetyECG at about day 14 of the first cycleDay 14 of cycle 1DueBooked with the day-14 blood tests
Medication safetyAromatase inhibitor startAt initiationCompleted todayLetrozole 2.5 mg daily; postmenopausal for two years, so no ovarian suppression needed
ImagingBone density (DXA)Baseline at aromatase inhibitor start, then every 2 yearsCompleted todayLumbar spine T-score -1.8, femoral neck -1.3: low bone mass
Medication safetyZoledronic acid: kidney function, calcium, and dental checkBefore each infusionCompleted todayCreatinine 0.8, eGFR 87, calcium 9.4; dental check normal; first infusion today
LaboratoryCalcium and vitamin D adequacyOngoing on an aromatase inhibitorCompleted today25-hydroxyvitamin D 22 ng/mL, insufficient; vitamin D3 started
LaboratoryLipid panelPeriodically on an aromatase inhibitor, by cardiovascular riskCompleted todayTotal cholesterol 208, HDL 62, LDL 124, triglycerides 110 mg/dL
ExaminationAromatase inhibitor joint pain and musculoskeletal reviewEvery visitCompleted todayBaseline: mild knee stiffness from osteoarthritis
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted today25.5 cm on each side; no swelling after nodal radiation
ExaminationCancer-related history and physical examinationEvery 3 to 6 months for the first 3 yearsCompleted todayNo signs of recurrence
ImagingMammogram after breast-conserving treatment6 to 12 months after radiation, then yearlyDueBetween six and twelve months after radiation
Self-managementWritten monitoring schedule and survivorship care planAt the start of adjuvant therapyCompleted todayMonitoring calendar and treatment summary given; 150 minutes of activity a week; alcohol at or below one drink a day

Goal progress:

Guideline basis: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026); Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Oncology ECG and blood tests at about day 14. Sick visits through the oncology nurse line for fever. Primary care monitoring visit at the start of the fourth cycle. Next scheduled visit 2026-09-08: monitoring visit at the start of the fourth ribociclib cycle. [S]